Science Current Events | Science News | Brightsurf.com
 

Rejected Alzheimer's drug shows new potential

July 31, 2012

Study suggests that latrepirdine, which previously failed in clinical trials, may be successful if tested on patients with earlier stages of the disease

An international team of scientists led by researchers at Mount Sinai School Medicine have discovered that a drug that had previously yielded conflicting results in clinical trials for Alzheimer's disease effectively stopped the progression of memory deterioration and brain pathology in mouse models of early stage Alzheimer's disease. The findings, published July 31, 2012 in Molecular Psychiatry, demonstrate renewed potential for this compound and could lead to clinical trials in patients with early stages of the disease.

Latrepirdine, known commercially as Dimebon, was initially sold as an antihistamine in Russia, approved for use there in 1983. In the 1990s, researchers at the Institute of Physiologically Active Compounds in Moscow determined that the compound appeared effective in treating Alzheimer's disease in animals. They continued their research in humans and performed several studies, including Phase I and II trials, all of which showed significant and sustained improvement in cognitive behavior with minimal side effects. The Phase II trials, performed in Russia, were overseen by U.S. Alzheimer's researchers, including Mary Sano, PhD, Director of the Mount Sinai Alzheimer's Disease Research Center.

However, when research was continued in the United States in a Phase III trial, the drug did not demonstrate any improvement in people with the disease, causing the sponsors to halt further clinical study of the drug in Alzheimer's disease. Some researchers have speculated that the Russian patients might have had different disease stage or subtype of Alzheimer's, and therefore were more responsive to treatment than the patients in the Phase III trials in the United States.

Before the failed trials were announced, researchers at Mount Sinai School of Medicine, led by Sam Gandy, MD, PhD, Professor of Neurology, and Psychiatry, and Director of the Mount Sinai Center for Cognitive Health, began studying the mechanism of action behind latrepirdine in the current study, which is supported by the Cure Alzheimer's Fund.

Dr. Gandy's team randomly administered either latrepirdine or placebo to mice engineered to present the early stages of Alzheimer's disease and found that the drug halted both behavioral decline and progression of neuropathology. In evaluating how latrepirdine improved memory, John Steele, PhD, a neuroscience graduate student working with Dr. Gandy, and Lenard Lachenmayer, MD, a postdoctoral fellow working under the supervision of Zhenyu Yue, PhD, Associate Professor of Neurology at Mount Sinai, found that the drug enhanced autophagy, the so-called "self-eating" process of cells that protects the brain from neurodegeneration.

"When we learned that latrepirdine failed in patients in the United States in 2010, scientists around the world were disappointed and perplexed," Dr. Gandy said. "We wanted to find out why the drug did so well in Russia but then showed no effect in the global studies. The findings from our animal model studies indicated that this drug should not be discarded, and that, if its mechanism of action can be optimized, it still has potential."

Dr. Sano points out that not only did latrepirdene have significant and sustained effect in the Russian study but it also showed a mild effect in one study of patients with Huntington's disease.

"Since cognitive benefit is what really matters to patients and families, it is critical that we explore every mechanism by which it might occur," Dr. Sano said.

"While this is just the beginning, our research shows that this previously cast-off drug still has strong therapeutic promise," Dr. Gandy said. "Autophagy drugs are believed to hold great promise for a range of neurodegenerative diseases, and these data raise the question of whether further basic science work on latrepirdine might lead to optimization of the drug so that a more potent drug could be developed, and subsequently tested in human clinical trials.

"This is especially true since we know that latrepirdine is an extremely safe drug and in view of the recent failure of the first key trial of the drug bapineuzumab," Dr. Gandy added. "Also, as may be the case with all amyloid-lowering drugs, initiating latrepirdine trials before amyloid deposition begins may be the key. Now, with the new brain amyloid scans that began at Mount Sinai in June, we can easily establish who those patients are."

Looking ahead, Drs. Gandy, Yue, and their collaborators are planning to test latrepirdine in mouse models of other protein buildup diseases such as Parkinson's disease, Lewy body dementia, and chronic traumatic encephalopathy, the Alzheimer's-like condition athletes endure from boxing, football and hockey. Dr. Sano notes that so few agents show any improvement in cognition that it is critical that to exhaust every potential lead.

Mount Sinai has a long-standing legacy of critical breakthroughs in team research in Alzheimer's disease. Dr. Gandy is an internationally-renowned expert in understanding the amyloid plaques characteristic of Alzheimer's disease, and he led a team of researchers to the discovery of the first drugs that reduced amyloid buildup. Dr. Sano is a world leader in designing clinical trials to find treatments and preventions for cognitive loss and Alzheimer's disease. Together, their labs and the Mount Sinai Alzheimer's Disease Research Center and Center for Cognitive Health are focused on a strategic approach to translating clinical challenges into bench investigations and back.

The Mount Sinai Hospital / Mount Sinai School of Medicine


Related Alzheimer's Disease Current Events and Alzheimer's Disease News Articles


Leaky blood-brain barrier linked to Alzheimer's disease
Researchers using contrast-enhanced MRI have identified leakages in the blood-brain barrier (BBB) of people with early Alzheimer's disease (AD), according to a new study published online in the journal Radiology.

Vicious circle of platelets
They were published in the current issue of the renowned journal "Science Signaling". The scientists provide evidence for the first time that treatment of Alzheimer transgenic model mice with an anti-platelet drug leads to significantly reduced amyloid plaques in cerebral vessels.

Study paves way for new therapies in fight against calcium disorders
A study led by researchers at Georgia State University provides new insights into the molecular basis of human diseases resulting from mutations in the calcium-sensing receptor (CaSR), a protein found in cell membranes.

Ancient anti-inflammatory drug salicylic acid has cancer-fighting properties
Scientists from the Gladstone Institutes have identified a new pathway by which salicylic acid--a key compound in the nonsteroidal anti-inflammatory drugs aspirin and diflunisal--stops inflammation and cancer.

The deadly toxin acrolein has a useful biological role
Scientists from RIKEN in Japan have discovered that acrolein--a toxic substance produced in cells during times of oxidative stress--in fact may play a role in preventing the process of fibrillation, an abnormal clumping of peptides that has been associated with Alzheimer's disease and other neural diseases.

Researchers identify immune genes tied to common, deadly brain cancer
Researchers have identified a group of immune system genes that may play a role in how long people can live after developing a common type of brain cancer called glioblastoma multiforme, a tumor of the glial cells in the brain.

Can Alzheimer's disease-associated peptide fight bacterial infection?
Amyloid-ß is a sticky peptide notorious for forming destructive plaques in the brains of Alzheimer's disease patients, but a new study suggests that it may also serve a protective function as an antimicrobial peptide.

Human amyloid-beta acts as natural antibiotic in the brains of animal models
A new study from Massachusetts General Hospital (MGH) investigators provides additional evidence that amyloid-beta protein - which is deposited in the form of beta-amyloid plaques in the brains of patients with Alzheimer's disease - is a normal part of the innate immune system, the body's first-line defense against infection.

Progranulin and dementia -- a blood sample does not tell the full story!
Progranulin is a central protein in both neuronal survival and neurodegenerative diseases. It is thus not surprising that altered progranulin levels represent a universal theme shared across several common neurodegenerative diseases.

PET imaging with special tracer can detect and diagnose early Alzheimer's disease
The effort to find ways to detect and diagnose preclinical Alzheimer's disease (AD) has taken a big step forward with the use of positron emission tomography (PET), a "nuclear medicine" for imaging processes in the body, when PET is used with a special 'tracer' that binds to the amyloid plaques in the brain that are a characteristic cause of AD.
More Alzheimer's Disease Current Events and Alzheimer's Disease News Articles

Alzheimer's Disease: What If There Was a Cure?: The Story of Ketones

Alzheimer's Disease: What If There Was a Cure?: The Story of Ketones
by Mary T. Newport (Author)


Acting on new research showing that medium-chain fatty acids, which act like an alternative fuel in the insulin-deficient Alzheimer's brain, can sometimes reverse or at least stabilize the disease, author Dr. Mary T. Newport has demonstrated through her care for her husband that there is hope, relief, and perhaps a cure.

Alzheimer?s: A Complete Guide to Understanding and Managing Alzheimer’s Disease

Alzheimer?s: A Complete Guide to Understanding and Managing Alzheimer’s Disease
by Julia Chandler (Author)


Understanding and Managing Alzheimer’s Disease Alzheimer's disease is a progressive form of dementia that kills brain cells, leading to continual loss of memory and intellectual capacity, and eventual death. Sadly, no treatment has been found to stop its progression. This book provides a valuable resource for both individuals struggling with the effects of Alzheimer's and those who care for them. By reading this book, you'll learn:
• The many facets and stages of the disease
• The signs, symptoms, and diagnosis of Alzheimer's
• The different stages of Alzheimer's, and treatment options currently available
• Diet and nutritional considerations
• Comprehensive care plans for each stage of the disease: early, middle, and late The ongoing struggle with...

The Alzheimer's Prevention & Treatment Diet

The Alzheimer's Prevention & Treatment Diet
by Richard S. Isaacson MD (Author), Christopher N. Ochner PhD (Author)


Alzheimer’s disease (AD) is a type of dementia that can be very hard on both the patient and the caregiver. Currently, five million Americans have been diagnosed with AD--and that number is likely to triple by 2050. While the cause of Alzheimer’s disease is still a mystery, new research has increased our knowledge of certain aspects of the disease. Perhaps most significant, studies show that proper diet may make a real difference, not only in slowing the progression of AD, but also in preventing it. In this groundbreaking book, a notable expert on Alzheimer’s disease has teamed up with a leading researcher of nutrition to create a unique guide to understanding and managing this serious condition. The Alzheimer’s Prevention & Treatment Diet outlines a cutting-edge nutritional...

Learning to Speak Alzheimer's: A Groundbreaking Approach for Everyone Dealing with the Disease

Learning to Speak Alzheimer's: A Groundbreaking Approach for Everyone Dealing with the Disease
by Joanne Koenig Coste (Author), Robert Butler (Foreword)


More than four million Americans suffer from Alzheimer’s, and as many as twenty million have close relatives or friends with the disease. Revolutionizing the way we perceive and live with Alzheimer’s, Joanne Koenig Coste offers a practical approach to the emotional well-being of both patients and caregivers that emphasizes relating to patients in their own reality. Her accessible and comprehensive method, which she calls habilitation, works to enhance communication between carepartners and patients and has proven successful with thousands of people living with dementia. Learning to Speak Alzheimer’s also offers hundreds of practical tips, including how to · cope with the diagnosis and adjust to the disease’s progression · help the patient talk about the illness · face the...

Neurophilosophy and Alzheimer's Disease (Research and Perspectives in Alzheimer's Disease)

Neurophilosophy and Alzheimer's Disease (Research and Perspectives in Alzheimer's Disease)
by Patricia S. Churchland (Editor)


Any mention of the relationship, still poorly understood, between body (or brain) and mind invariably invokes the name of Descartes, who is often thought of as the father of modern philosophy and perhaps of neurophilosophy. Although a native of the heart of France (the region around Tours), Rene Descartes travelled widely, as everyone knows, especially to Holland and Sweden. It should come as no surprise, that the Congress of Neurophilosophy and Alzheimer's Disease was the first in the series of Fondation Ipsen Colloques Medecine et Recherche to be held outside France. The meeting was held in San Diego (California) on January 11, 1991. This venue was chosen for a number of reasons. The University of California San Diego is without doubt one of the most dynamic universities today. A good...

The 36-Hour Day: A Family Guide to Caring for People Who Have Alzheimer Disease, Related Dementias, and Memory Loss

The 36-Hour Day: A Family Guide to Caring for People Who Have Alzheimer Disease, Related Dementias, and Memory Loss
by Nancy L. Mace (Author), Peter V. Rabins (Author)


The most trusted guide for caring for persons with Alzheimer's disease, memory loss, and dementia disorders-now revised and updated with practical and legal advice and compassionate guidance for families and caregivers.

When someone in your family suffers from Alzheimer's disease or other related memory loss diseases, both you and your loved one face immense challenges. For over thirty years, this book has been the trusted bible for families affected by dementia disorders. Now completely revised and updated, this guide features the latest information on the causes of dementia, managing the early stages of dementia, the prevention of dementia, and finding appropriate living arrangements for the person who has dementia when home care is no longer an option. You'll learn:
The basic...

Alzheimer ’s Disease and Risks: Simplified

Alzheimer ’s Disease and Risks: Simplified


This book is a comprehensive guide and review for anyone who wishes to learn about the Alzheimer’s disease. You may have someone in the family who suffers from it or you may just be curious to learn about it. Regardless, this book is sure to benefit you by providing you a complete interface of the disease. We will start from the very basics on what the disease actually is, how it starts and its scientific mechanism in comprehensive way.
In addition, the signs and symptoms will be talked about in detail in order to enable you to make an efficient diagnosis if you come across such an individual. We will also talk about who is more likely to be affected by it, how it can be treated, prevented and how to deal with it. This will be in terms of both the patient as well as the family....

Alzheimer's Treatment Alzheimer's Prevention: A Patient and Family Guide, 2012 Edition

Alzheimer's Treatment Alzheimer's Prevention: A Patient and Family Guide, 2012 Edition
by Dr. Richard S Isaacson MD (Author)


Harvard-trained Neurologist Dr. Richard Isaacson answers the most common patient and caregiver questions on the treatment and prevention of Alzheimer's disease (AD). He shares his cutting edge, comprehensive approach in the fight against AD, the greatest public health crisis today. This groundbreaking book has been written especially for patients, caregivers, family members, and allied healthcare professionals. Dr. Isaacson writes in easy to understand terms and easy to read (larger-type) print to help educate and inform those confronting AD. He outlines his comprehensive and scientifically-based approach that includes a comprehenisve 9-week diet and nutrition plan, with examples of what to eat, what not to eat, and a food terminology guide to help read and understand nutrition labels. ...

The Inheritance: A Family on the Front Lines of the Battle Against Alzheimer's Disease

The Inheritance: A Family on the Front Lines of the Battle Against Alzheimer's Disease
by Niki Kapsambelis (Author)


An inspiring race against time: The courageous, hopeful story of the one family who may hold the key to finding a cure for Alzheimer’s disease.

Every sixty-nine seconds, someone is diagnosed with Alzheimer’s disease. Of the top ten killers, it is the only disease for which there is no cure or treatment. For most people, there is nothing that they can do to fight back. But one family is doing all they can.

The DeMoe family has the most devastating form of the disease that there is: early onset Alzheimer’s, an inherited genetic mutation that causes the disease in 100 percent of cases, and has a 50 percent chance of being passed onto the next generation. Of the six DeMoe children whose father had it, five have inherited the gene; the sixth, Karla, has inherited...

The Alzheimer's Prevention Program: Keep Your Brain Healthy for the Rest of Your Life

The Alzheimer's Prevention Program: Keep Your Brain Healthy for the Rest of Your Life
by Gary Small (Author), Gigi Vorgan (Author)


Want to keep Alzheimer’s at bay for years—ideally, forever? Prevention is the way, and this is the guide. Now in paperback and updated throughout, The Alzheimer’s Prevention Program is essential for everyone with a family history of Alzheimer’s, and for the 80 million baby boomers who worry whenever they forget someone’s name. It’s the book that shows how to strengthen memory and avoid everyday lapses. How to incorporate the top ten brain-protecting foods into your diet. How to cross-train your brain, exercising both the right and left hemisphere. And how to reduce stress, a risk factor for developing dementia and Alzheimer’s, through meditation and 11 other relaxation strategies.

Written by the New York Times bestselling authors of The Memory Bible, this book is...

© 2017 BrightSurf.com